Press Releases
Press Releases
-
August 5, 2021
Kite and Appia Bio Announce Collaboration to Research and Develop Allogeneic Cell Therapies for Cancer -
August 4, 2021
BioNTech Completes Acquisition of Kite’s Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, Maryland -
August 3, 2021
Gilead Sciences Endows Its Foundation With More Than $200 Million to Support Health Justice, Community Giving and Employee Match Program -
July 29, 2021
Gilead Sciences Announces Second Quarter 2021 Financial Results -
July 19, 2021
BioNTech to Acquire Kite’s Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, MD -
July 17, 2021
New Phase 3 Data Support the Sustained, Long-Acting Efficacy of Lenacapavir, Gilead's Investigational HIV-1 Capsid Inhibitor -
July 17, 2021
Four-Year Biktarvy® Data Presented at IAS 2021 Demonstrate High Efficacy and Durable Viral Suppression in Treatment-Naïve Adults -
July 15, 2021
Gilead Sciences to Release Second Quarter 2021 Financial Results on Thursday, July 29, 2021 -
July 12, 2021
Gilead to Present New Data at IAS 2021 Demonstrating the Company’s Commitment to Advancing Innovation in HIV Research -
June 28, 2021
Gilead Submits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting Capsid Inhibitor for the Treatment of HIV-1 in People With Limited Therapy Options